TAS-2940

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameTAS-2940
Drug Alias NameTAS-2940
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTaiho Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaiho Oncology Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A